Dietary soy and tea combinations for prevention of breast and prostate cancers by targeting metabolic syndrome elements in mice

American Journal of Clinical Nutrition

Volumn 86, Issue 3, 2007, Pages

  Zhou, Jin Rong ^a,b   Li, Linglin ^a   Pan, Weijun ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer prevention; IGF I; Insulin like growth factor I; Leptin; Metabolic syndrome; Soy; Synergy; Tea

Indexed keywords

ADIPONECTIN; ESTROGEN; LEPTIN; SOMATOMEDIN C; SOYBEAN PROTEIN; TESTOSTERONE;

ABDOMINAL FAT; ANIMAL; ARTICLE; BLOOD; BREAST TUMOR; DIET; DIET THERAPY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; MALE; METABOLIC SYNDROME X; METABOLISM; MOUSE; PROSTATE TUMOR; RANDOMIZATION; TEA;

ABDOMINAL FAT; ADIPONECTIN; ANIMALS; BREAST NEOPLASMS; DIET; DRUG SYNERGISM; ESTROGENS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LEPTIN; MALE; METABOLIC SYNDROME X; MICE; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; SOYBEAN PROTEINS; TEA; TESTOSTERONE;

EID: 40349110859     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.1093/ajcn/86.3.882s     Document Type: Conference Paper

References (73)

1. Stoll BA. Western nutrition and the insulin resistance syndrome: a link to breast cancer. Eur J Clin Nutr 1999;53:83-7. (Pubitemid 29082524)
2. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-91. (Pubitemid 39025053)
3. Sinagra D, Amato C, Scarpilta AM, et al. Metabolic syndrome and breast cancer risk. Eur Rev Med Pharmacol Sci 2002;6:55-9. (Pubitemid 36395320)
4. Okobia MN, Bunker CH, Zmuda JM, et al. Anthropometry and breast cancer risk in Nigerian women. Breast J 2006;12:462-6. (Pubitemid 44337440)
5. Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 2006;119:236-8.
6. Lund Haheim L, Wisloff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 2006;164:769-74. (Pubitemid 44522081)
7. Hammarsten J, Hogstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005;41:2887-95. (Pubitemid 41713128)
8. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 2004;13:1646-50. (Pubitemid 39331887)
9. Hammarsten J, Hogstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 2004;13:47-55. (Pubitemid 38455847)
10. Scheen A, Lefebvre P. Insulin action in man. Diabetes Metab 1996;22:105-10.
11. Whitelaw D, Gilbey S. Insulin resistance. Ann Clin Biochem 1998;35:567-83. (Pubitemid 28434568)
12. Mayer-Davis EJ, Monaco JH, Hoen HM, et al. Dietary fat and insulin sensitivity in a triethnic population: the role of obesity. The Insulin Resistance Atherosclerosis Study (IRAS). Am J Clin Nutr 1997;65:79-87. (Pubitemid 27020463)
13. Bruning PF, Bonfrer JM, van Noord PA, Hart AA, Jong-Bakker M, Nooijen WJ. Insulin resistance and breast-cancer risk. Int J Cancer 1992;52:511-6.
14. Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, Page D, Goodwin PJ. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 1998;47:111-20. (Pubitemid 28046082)
15. Yu H, Jin F, Shu XO, et al. Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 2002;11:705-12. (Pubitemid 34851903)
16. Malin A, Dai Q, Yu H, et al. Evaluation of the synergistic effect of insulin resistance and insulin-like growth factors on the risk of breast carcinoma. Cancer 2004;100:694-700. (Pubitemid 38176845)
17. Chemoprevention Working Group. Prevention of cancer in the next millennium: report of the chemoprevention working group to the American Association for Cancer Research. Cancer Res 1999;59:4743-58.
18. Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994;21:113-31. (Pubitemid 24127628)
19. Yang CS, Wang ZY. Tea and cancer J Natl Cancer Inst 1993;85:1038-49. (Pubitemid 23199184)
20. Zhou J-R, Yu L, Zhong Y, Blackburn GL. Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. J Nutr 2003;133:516-21. (Pubitemid 36172909)
21. Zhou J-R, Yu L, Mai Z, Blackburn GL. Combined inhibition of estrogen-dependent human breast carcinoma by soy and tea bioactive components in mice. Int J Cancer 2004;108:8-14. (Pubitemid 37444437)
22. Steel RGD, Torrie JH. Principles and procedures of statistics: a biometrical approach. 2nd ed. New York, NY: McGraw-Hill Book Company, Inc, 1980.
23. Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 2000;60:2190-6. (Pubitemid 30225182)
24. Lavigne C, Marette A, Jacques H. Cod and soy proteins compared with casein improve glucose tolerance and insulin sensitivity in rats. Am J Physiol Endocrinol Metab 2000;278:E491-500. (Pubitemid 30149394)
25. Sanchez A, Hubbard RW. Plasma amino acids and the insulin/glucagon ratio as an explanation for the dietary protein modulation of atherosclerosis. Med Hypotheses 1991;36:27-32.
26. Sugano M, Ishiwaki N, Nagata Y, Imaizumi K. Effects of arginine and lysine addition to casein and soya-bean protein on serum lipids, apolipoproteins, insulin and glucagon in rats. Br J Nutr 1982;48:211-21. (Pubitemid 13240160)
27. Akahoshi A, Koba K, Ichinose F, et al. Dietary protein modulates the effect of CLA on lipid metabolism in rats. Lipids 2004;39:25-30. (Pubitemid 38296123)
28. Nagasawa A, Fukui K, Funahashi T, et al. Effects of soy protein diet on the expression of adipose genes and plasma adiponectin. Horm Metab Res 2002;34:635-9. (Pubitemid 36398698)
29. Nagasawa A, Fukui K, Kojima M, et al. Divergent effects of soy protein diet on the expression of adipocytokines. Biochem Biophys Res Commun 2003;311:909-14. (Pubitemid 37393404)
30. Ali AA, Velasquez MT, Hansen CT, Mohamed AI, Bhathena SJ. Effects of soybean isoflavones, probiotics, and their interactions on lipid metabolism and endocrine system in an animal model of obesity and diabetes. J Nutr Biochem 2004;15:583-90. (Pubitemid 39470212)
31. Ali AA, Velasquez MT, Hansen CT, Mohamed AI, Bhathena SJ. Modulation of carbohydrate metabolism and peptide hormones by soybean isoflavones and probiotics in obesity and diabetes. J Nutr Biochem 2005;16:693-9. (Pubitemid 41460524)
32. Bu L, Setchell KD, Lephart ED. Influences of dietary soy isoflavones on metabolism but not nociception and stress hormone responses in ovariectomized female rats. Reprod Biol Endocrinol 2005;3:58.
33. Szkudelski T, Nogowski L, Pruszynska-Oszmalek E, Kaczmarek P, Szkudelska K. Genistein restricts leptin secretion from rat adipocytes. J Steroid Biochem Mol Biol 2005;96:301-7. (Pubitemid 41080511)
34. Ae Park S, Choi MS, Cho SY, et al. Genistein and daidzein modulate hepatic glucose and lipid regulating enzyme activities in C57BL/KsJ-db/db mice. Life Sci 2006;79:1207-13. (Pubitemid 44144498)
35. Wu AH, Stanczyk FZ, Martinez C, et al. A controlled 2-mo dietary fat reduction and soy food supplementation study in postmenopausal women. Am J Clin Nutr 2005;81:1133-41. (Pubitemid 41724956)
36. Goodman-Gruen D, Kritz-Silverstein D. Usual dietary isoflavone intake is associated with cardiovascular disease risk factors in postmenopausal women. J Nutr 2001;131:1202-6. (Pubitemid 32275100)
37. Yamashita T, Sasahara T, Pomeroy SE, Collier G, Nestel PJ. Arterial compliance, blood pressure, plasma leptin, and plasma lipids in women are improved with weight reduction equally with a meat-based diet and a plant-based diet. Metabolism 1998;47:1308-14. (Pubitemid 28523460)
38. Jenkins DJ, Wolever TM, Spiller G, et al. Hypocholesterolemic effect of vegetable protein in a hypocaloric diet. Atherosclerosis 1989;78:99-107. (Pubitemid 19195479)
39. Kao YH, Hiipakka RA, Liao S. Modulation of obesity by a green tea catechin. Am J Clin Nutr 2000;72:1232-4.
40. Wolfram S, Wang Y, Thielecke F. Anti-obesity effects of green tea: from bedside to bench. Mol Nutr Food Res 2006;50:176-87. (Pubitemid 43325659)
41. Ashida H, Furuyashiki T, Nagayasu H, et al. Anti-obesity actions of green tea: possible involvements in modulation of the glucose uptake system and suppression of the adipogenesis-related transcription factors. Biofactors 2004;22:135-40. (Pubitemid 40921775)
42. Sayama K, Lin S, Zheng G, Oguni I. Effects of green tea on growth, food utilization and lipid metabolism in mice. In Vivo 2000;14:481-4. (Pubitemid 30616068)
43. Westerterp-Plantenga MS, Lejeune MP, Kovacs EM. Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation. Obes Res 2005;13:1195-204.
44. Agurs-Collins T, Adams-Campbell LL, Kim KS, Cullen KJ. Insulin-like growth factor-1 and breast cancer risk in postmenopausal African-American women. Cancer Detect Prev 2000;24:199-206. (Pubitemid 30656726)
45. Allen NE, Roddam AW, Allen DS, et al. A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer 2005;92:1283-7. (Pubitemid 40604405)
46. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6. (Pubitemid 28067285)
47. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer J Clin Endocrinol Metab 2000;85:4258-65. (Pubitemid 32055383)
48. Probst-Hensch NM, Wang H, Goh VH, Seow A, Lee HP, Yu MC. Determinants of circulating insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations in a cohort of Singapore men and women. Cancer Epidemiol Biomarkers Prev 2003;12:739-46. (Pubitemid 36993164)
49. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-106. (Pubitemid 34830730)
50. Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, Weiss NS. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 2005;103:76-84. (Pubitemid 39665459)
51. Khalil DA, Lucas EA, Juma S, Smith BJ, Payton ME, Arjmandi BH. Soy protein supplementation increases serum insulin-like growth factor-I in young and old men but does not affect markers of bone metabolism. J Nutr 2002;132:2605-8. (Pubitemid 35013242)
52. Gann PH, Kazer R, Chatterton R, et al. Sequential, randomized trial of a low-fat, high-fiber diet and soy supplementation: effects on circulating IGF-I and its binding proteins in premenopausal women. Int J Cancer 2005;116:297-303. (Pubitemid 40967269)
53. Arjmandi BH, Lucas EA, Khalil DA, et al. One year soy protein supplementation has positive effects on bone formation markers but not bone density in postmenopausal women. Nutr J 2005;Feb 23;4-8.
54. Woodside JV, Campbell MJ, Denholm EE, et al. Short-term phytoestrogen supplementation alters insulin-like growth factor profile but not lipid or antioxidant status. J Nutr Biochem 2006;17:211-5. (Pubitemid 43247416)
55. Sanderson M, Shu XO, Yu H, et al. Insulin-like growth factor-I, soy protein intake, and breast cancer risk. Nutr Cancer 2004;50:8-15. (Pubitemid 39587600)
56. Nagata C, Shimizu H, Takami R, Hayashi M, Takeda N, Yasuda K. Dietary soy and fats in relation to serum insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 levels in premenopausal Japanese women. Nutr Cancer 2003;45:185-9. (Pubitemid 37022791)
57. Adams KF, Newton KM, Chen C, et al. Soy isoflavones do not modulate circulating insulin-like growth factor concentrations in an older population in an intervention trial. J Nutr 2003;133:1316-9. (Pubitemid 36548700)
58. Vrieling A, Voskuil DW, Bueno de Mesquita HB, et al. Dietary determinants of circulating insulin-like growth factor (IGF)-I and IGF binding proteins 1, -2 and -3 in women in the Netherlands. Cancer Causes Control 2004;15:787-96. (Pubitemid 39335575)
59. Maskarinec G, Takata Y, Murphy SP, Franke AA, Kaaks R. Insulin-like growth factor-1 and binding protein-3 in a 2-year soya intervention among premenopausal women. Br J Nutr 2005;94:362-7. (Pubitemid 41404278)
60. Fisher B, Dignam J, Bryant J, et al. Five vs more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-42. (Pubitemid 26374506)
61. Gonzalez RR, Cherfils S, Escobar M, et al. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem 2006;281:26320-8. (Pubitemid 44401840)
62. Sulkowska M, Golaszewska J, Wincewicz A, Koda M, Baltaziak M, Sulkowski S. Leptin - from regulation of fat metabolism to stimulation of breast cancer growth. Pathol Oncol Res 2006;12:69-72. (Pubitemid 44197171)
63. Garofalo C, Koda M, Cascio S, et al. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res 2006;12:1447-53.
64. Miyoshi Y, Funahashi T, Tanaka S, et al. High expression of leptin receptor mRNA in breast cancer tissue predicts poor prognosis for patients with high, but not low, serum leptin levels. Int J Cancer 2006;118:1414-9.
65. Chen DC, Chung YF, Yeh YT, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2006;237:109-14.
66. Hsing AW, Chua S Jr, Gao YT, et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 2001;93:783-9. (Pubitemid 32514802)
67. Stattin P, Kaaks R, Johansson R, et al. Plasma leptin is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12:474-5. (Pubitemid 36578490)
68. Stattin P, Soderberg S, Hallmans G, et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab 2001;86:1341-5. (Pubitemid 32323026)
69. Lagiou P, Signorello LB, Trichopoulos D, Tzonou A, Trichopoulou A, Mantzoros CS. Leptin in relation to prostate cancer and benign prostatic hyperplasia. Int J Cancer 1998;76:25-8. (Pubitemid 28164564)
70. Baillargeon J, Platz EA, Rose DP, et al. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev 2006;15:1331-5. (Pubitemid 44125290)
71. Gade-Andavolu R, Cone LA, Shu S, Morrow A, Kowshik B, Andavolu MV. Molecular interactions of leptin and prostate cancer. Cancer J 2006;12:201-6. (Pubitemid 43894336)
72. Chang S, Hursting SD, Contois JH, et al. Leptin and prostate cancer. Prostate 2001;46:62-7. (Pubitemid 32157777)
73. Saglam K, Aydur E, Yilmaz M, Goktas S. Leptin influences cellular differentiation and progression in prostate cancer. J Urol 2003;169:1308-11. (Pubitemid 36323773)